KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Payables (2016 - 2026)

Supernus Pharmaceuticals has reported Payables over the past 15 years, most recently at $107.8 million for Q4 2025.

  • Quarterly Payables rose 41.19% to $107.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $107.8 million through Dec 2025, up 41.19% year-over-year, with the annual reading at $107.8 million for FY2025, 41.19% up from the prior year.
  • Payables was $107.8 million for Q4 2025 at Supernus Pharmaceuticals, down from $108.6 million in the prior quarter.
  • Over five years, Payables peaked at $498.3 million in Q4 2022 and troughed at $70.1 million in Q1 2021.
  • The 5-year median for Payables is $82.8 million (2023), against an average of $130.1 million.
  • Year-over-year, Payables soared 545.81% in 2021 and then crashed 84.03% in 2023.
  • A 5-year view of Payables shows it stood at $117.7 million in 2021, then surged by 323.43% to $498.3 million in 2022, then crashed by 84.03% to $79.6 million in 2023, then fell by 4.04% to $76.4 million in 2024, then soared by 41.19% to $107.8 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Payables are $107.8 million (Q4 2025), $108.6 million (Q3 2025), and $77.7 million (Q2 2025).